David A Pattison
Overview
Explore the profile of David A Pattison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Emmett L, Subramaniam S, Crumbaker M, Joshua A, Sandhu S, Nguyen A, et al.
Lancet Oncol
. 2025 Feb;
26(3):291-299.
PMID: 39956124
Background: Interim analysis of the ENZA-p trial showed improved prostate-specific antigen (PSA) progression-free survival with the addition of lutetium-177 [Lu]Lu-prostate-specific membrane antigen (PSMA)-617 to enzalutamide as first-line treatment of metastatic...
2.
Bailey D, Willowson K, OKeefe G, Goodman S, Patford S, McGill G, et al.
J Nucl Med
. 2025 Jan;
66(2):315-322.
PMID: 39819695
Our aim is to report methodology that has been developed to calibrate and verify PET and SPECT quantitative image accuracy and quality assurance for use with nonstandard radionuclides, especially with...
3.
Wootton E, Wong C, Love A, Pattison D
JCEM Case Rep
. 2024 Dec;
2(12):luae222.
PMID: 39659386
No abstract available.
4.
Azad A, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt A, et al.
Lancet Oncol
. 2024 Sep;
25(10):1267-1276.
PMID: 39293461
Background: Lutetium-177 [Lu]Lu-prostate-specific membrane antigen (PSMA)-617 improves survival and quality of life in patients with metastatic castration-resistant prostate cancer, but whether it confers a benefit in hormone-sensitive disease is unknown....
5.
Grady E, Grady E, Pattison D, Redman S, Satoh Y
AJR Am J Roentgenol
. 2024 May;
224(2):e2431348.
PMID: 38691414
No abstract available.
6.
Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua A, Weickhardt A, et al.
Lancet Oncol
. 2024 Apr;
25(5):563-571.
PMID: 38621400
Background: Enzalutamide and lutetium-177 [Lu]Lu-prostate-specific membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic castration-resistant prostate cancer. Androgen and PSMA receptors have a close intracellular relationship, with data...
7.
Griffiths M, Pattison D, Latter M, Kuan K, Taylor S, Tieu W, et al.
J Nucl Med
. 2024 Feb;
65(4):664.
PMID: 38423783
No abstract available.
8.
Tariq A, Pearce A, Rhee H, Kyle S, Raveenthiran S, Pelecanos A, et al.
Eur Urol Focus
. 2024 Jan;
10(5):770-778.
PMID: 38195354
Background: Accurate primary staging of renal cancer with conventional imaging is challenging. Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) may serve to improve the accuracy of renal cancer...
9.
Buteau J, Moon D, Fahey M, Roberts M, Thompson J, Murphy D, et al.
Eur Urol Oncol
. 2023 Dec;
7(3):544-552.
PMID: 38061976
Background: Multiparametric magnetic resonance imaging (mpMRI) has an established role for the diagnosis of clinically significant prostate cancer (sPCa). The PRIMARY trial demonstrated that [Ga]Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT)...
10.
Hofman M, Emmett L, Sandhu S, Iravani A, Buteau J, Joshua A, et al.
Lancet Oncol
. 2023 Dec;
25(1):99-107.
PMID: 38043558
Background: The TheraP study reported improved prostate-specific antigen responses with lutetium-177 [Lu]Lu-PSMA-617 versus cabazitaxel in men with metastatic castration-resistant prostate cancer progressing after docetaxel. In this Article, we report the...